HanchorBio Secures FDA Orphan Drug Designation for Gastric Cancer Therapy HCB101
Event summary
- FDA granted Orphan Drug Designation to HCB101 for gastric cancer treatment on February 13, 2026.
- HCB101 is a next-generation CD47–SIRPα pathway inhibitor designed to minimize hematologic toxicities.
- Phase 1b/2a trial (NCT06771622) is assessing HCB101 in combination with ramucirumab and paclitaxel.
- Designation provides tax credits, FDA user fee exemptions, and potential for seven years of market exclusivity.
The big picture
HanchorBio's FDA Orphan Drug Designation for HCB101 underscores the unmet medical need in gastric cancer, particularly in the second-line setting where treatment options are limited. The designation validates HanchorBio's strategy of developing differentiated immunotherapies and positions HCB101 as a potential backbone immunotherapy across multiple solid tumor indications. The company's focus on minimizing hematologic toxicities and enhancing combination therapy potential aligns with broader industry trends toward more targeted and effective cancer treatments.
What we're watching
- Clinical Progress
- The pace at which HCB101 demonstrates efficacy in ongoing trials will determine its viability as a differentiated immunotherapy.
- Regulatory Strategy
- How HanchorBio leverages the Orphan Drug Designation incentives to accelerate U.S. and international development.
- Partnership Potential
- Whether HanchorBio can secure multinational collaborations to advance HCB101 and its broader immunotherapy pipeline.
Related topics